Citations

Showing 10 of 108094 citations.

The t(1;10)(p22;q24) TGFBR3/MGEA5 Translocation in Pleomorphic Hyalinizing Angiectatic Tumor, Myxoinflammatory Fibroblastic Sarcoma, and Hemosiderotic Fibrolipomatous Tumor
Sukov, William R. , Ro, Jae Y. , Liu, Huifei

Mayo Clinic

Archives of Pathology & Laboratory Medicine | July 6, 2018 | Volume: 143 | Issue: 2 | Pages: 212-221

10.5858/arpa.2017-0412-ra | PMID 29979612 Get It

Context.— Pleomorphic hyalinizing angiectatic tumor (PHAT) of soft parts, hemosiderotic fibrolipomatous tumor (HFLT), and myxoinflammatory fibroblastic sarcoma (MIFS) are 3 distinct entities of low-grade spindle cell mesenchymal neoplasm. These tumors have similar clinical presentations and partially overlapping but distinctive pathologic features. A recurrent translocation, t(1;10)(p22;q24), has been detected in a subset of PHAT, HFLT, MIFS, and HFLT/MIFS hybrid cases. Translocation t(1;10)(p22;q24) involves transforming growth factor β-receptor 3 (TGFBR3) and meningioma-expressed antigen 5 (MGEA5) genes on chromosomes 1p22 and 10q24, respectively. However, the percentage of translocation in PHAT, HFLT, and MIFS varies significantly among different studies. The relationship among these tumors has been a controversial topic among experts. Objective.— To discuss the diagnostic and functional significance of translocation t(1;10)(p22;q24) TGFBR3/MGEA5 rearrangement in HFLT, PHAT, and MIFS. Data Sources.— PubMed was used for this study. Conclusions.— Diagnosis of HFLT, PHAT, and MIFS is challenging because of a lack of unique morphologic, immunophenotypic, molecular, and cytogenetic markers. The recurrent t(1;10)(p22;q24) translocation and/or TGFBR3/MGEA5 rearrangement was reported in 55 patients, with a relatively even distribution among HFLT, PHAT, and MIFS (17 HFLT, 15 MIFS, 13 MIFS/HFLT, and 10 PHAT). This indicates that current morphology-based diagnostic criteria do not identify reliably the subset of soft tissue tumor with t(1;10) translocation. Genetic heterogeneity of these tumors is supported by the recent detection of a mutually exclusive, second recurrent genetic change, t(7;17) TOM1L2-BRAF translocation or BRAF amplification, in a subset of MIFS.
Use of objective evidence of myocardial ischemia to facilitate the diagnostic and prognostic distinction between type 2 myocardial infarction and myocardial injury
Sandoval, Yader , Sexter, Anne, Schulz, Karen , Apple, Fred S. , Smith, Stephen W.

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | July 6, 2018 | Volume: 9 | Issue: 1 | Pages: 62-69

10.1177/2048872618787796 | PMID 29979092 Get It

Aims: First, describe how acute myocardial infarction criteria are used to diagnose type 1 (T1MI) and 2 (T2MI) myocardial infarction. Second, determine whether subjective or objective criteria are used for T2MI. Third, examine outcomes for T2MI based on the presence or absence of objective evidence of myocardial ischemia compared with myocardial injury. Methods and results: Post-hoc analysis of UTROPIA (NCT02060760), a prospective, observational, cohort study involving 1640 consecutive emergency department patients with serial high-sensitivity cardiac troponin I among whom 74 (4.5%) had T1MI, 103 (6.3%) T2MI, and 245 (15%) myocardial injury. Compared with T1MI, patients with T2MI were less likely to have ischemic symptoms (97% vs. 83%), Q waves (24% vs. 1%), new ST-T wave changes (74% vs. 51%), new regional wall motion abnormality (64% vs. 11%), and a culprit lesion on coronary angiography (59% vs. 0%) (all p <0.05). T2MIs were more likely to be diagnosed using subjective criteria (symptoms alone) than T1MI (42% vs. 12%, p <0.0001). Patients with objective T2MI, but not subjective T2MI, had a two-fold increase in early mortality compared with myocardial injury, with 30- and 60-day hazard ratios (95% confidence interval) of 2.3 (0.9, 6.2) and 2.0 (0.9, 4.7) respectively. Conclusions: Among patients with T2MI, many cases are diagnosed using subjective criteria. The presence of objective evidence of myocardial ischemia may identify a higher-risk group of T2MI patients in whom early outcomes are worse than myocardial injury. Emphasis on using objective evidence of myocardial ischemia to diagnose T2MI may result in a more precise and specific disease definition.
Novel suprasellar location of desmoplastic infantile astrocytoma and ganglioglioma: a single institution’s experience
Naylor, Ryan M. , Wohl, Anton , Raghunathan, Aditya , Eckel, Laurence J. , Keating, Gesina F. , Raghunathan, Aditya , Daniels, David J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | July 6, 2018 | Volume: 22 | Issue: 4 | Pages: 397-403

10.3171/2018.4.peds17638 | PMID 29979130 Get It

OBJECTIVEThe aim of this study was to describe the clinical presentation, imaging appearance, and differential outcomes based on tumor location in 7 patients with desmoplastic infantile astrocytoma and desmoplastic infantile gangliogliomas (DIA/DIG).METHODSData of 7 patients with histopathology-proven DIA/DIGs and preoperative imaging were retrospectively reviewed, and age, sex, clinical presentation, imaging characteristics, tumor location, surgical procedure, postoperative morbidity, and overall mortality were recorded.RESULTSTwo subgroups of patients with DIA/DIGs were found to exist based on whether their tumor was located in the cerebral hemispheres or suprasellar region. Nearly all patients presented with rapidly enlarging head circumference regardless of tumor location. However, ocular abnormalities, including nystagmus and preference for downward gaze, were specific for patients with suprasellar disease. These patients experienced significant postoperative complications and had poor long-term outcomes. In contrast, patients with hemispheric tumors underwent more extensive resection than patients with suprasellar tumors, had uneventful postoperative courses, and had no documented long-term comorbidities.CONCLUSIONSPostoperative course and long-term outcome for patients with DIA/DIGs were correlated to the anatomical location and radiographic appearance of their tumor at presentation, despite having histologically and molecularly indistinguishable, WHO grade I tumors.
Family-Based Mindful Eating Intervention in Adolescents with Obesity: A Pilot Randomized Clinical Trial
Kumar, Seema , Croghan, Ivana T. , Biggs, Bridget K. , Croghan, Katrina, Prissel, Rose , Fuehrer, Debbie L., Donelan-Dunlap, Bonnie, Sood, Amit , Fuehrer, Debbie, Kumar, Seema , Biggs, Bridget K

Mayo Clinic

Children | July 6, 2018 | Volume: 5 | Issue: 7 | Pages: 93

10.3390/children5070093 | PMID 29986459 Get It

Mindfulness has gained attention in the treatment of obesity. However, there is a paucity of data on family-based training in mindful eating in children. The objective of this pilot randomized clinical trial was to evaluate the feasibility and acceptability of a family-based mindful eating intervention (MEI) in adolescents with obesity, and to compare the efficacy of the MEI versus standard dietary counseling (SDC) for decreasing weight and improving cardiometabolic risk markers. Twenty-two adolescents (age 14.5–17.9 years) and parent pairs were randomized to the MEI or SDC. The MEI was administered in four 90-min sessions over 10 weeks and SDC was provided at baseline, 12 weeks, and 24 weeks. Despite the requirement of more frequent visits with the MEI, adolescents and parents attended 100% of the sessions and there were no dropouts in that group. High density lipoprotein (HDL) cholesterol increased in the SDC group, but not in the MEI group. Adolescents receiving the MEI demonstrated an increase in awareness at 24 weeks (p = 0.01) and a decrease in distraction during eating at 12 weeks (p = 0.04), when compared with the SDC group. The family-based MEI showed feasibility and acceptability in adolescents with obesity. Future studies with more intense therapy and larger sample sizes are warranted to examine the role of mindful eating in treating pediatric obesity.
Posterior Embryotoxon, Corectopia, and Cerebellar Dysgenesis
Torrado, Laura A. , Ho, Mai‐Lan , Brodsky, Michael C., Ho, Mai-Lan , Ho, Mai Lan

Mayo Clinic

JAMA Ophthalmology | July 6, 2018 | Volume: 136 | Issue: 9 | Pages: 1062

10.1001/jamaophthalmol.2018.0101 | PMID 29978194 Get It

Neurosurgery and the rise of academic social media: what neurosurgeons should know
Linzey, Joseph R. , Graffeo, Christopher S. , Wang, Justin Z. , Haider, Ali S. , Alotaibi, Naif M.

Mayo Clinic

Journal of Neurosurgery | July 6, 2018 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.3171/2018.2.jns172817 | PMID 29979122 Get It

Laser ablation for mesial temporal epilepsy: a multi-site, single institutional series
Zimmerman, Richard S. , Brinkmann, Benjamin H. , Tatum, William O. , Crepeau, Amy Z. , Woodrum, David A. , Gorny, Krzysztof R. , Felmlee, Joel P. , Watson, Robert E. , Trenerry, Max R., Marsh, W. Richard , Wharen, Robert E. , Hoxworth, Joseph M. , Vibhute, Prasanna , Brinkmann, Benjamin H , Grewal, Sanjeet S. , Worrell, Gregory A. , Gupta, Vivek , Kaufmann, Timothy J. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurosurgery | July 6, 2018 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.3171/2018.2.jns171873 | PMID 29979119 Get It

OBJECTIVE Although it is still early in its application, laser interstitial thermal therapy (LiTT) has increasingly been employed as a surgical option for patients with mesial temporal lobe epilepsy. This study aimed to describe mesial temporal lobe ablation volumes and seizure outcomes following LiTT across the Mayo Clinic’s 3 epilepsy surgery centers. METHODS This was a multi-site, single-institution, retrospective review of seizure outcomes and ablation volumes following LiTT for medically intractable mesial temporal lobe epilepsy between October 2011 and October 2015. Pre-ablation and post-ablation follow-up volumes of the hippocampus were measured using FreeSurfer, and the volume of ablated tissue was also measured on intraoperative MRI using a supervised spline-based edge detection algorithm. To determine seizure outcomes, results were compared between those patients who were seizure free and those who continued to experience seizures. RESULTS There were 23 patients who underwent mesial temporal LiTT within the study period. Fifteen patients (65%) had left-sided procedures. The median follow-up was 34 months (range 12–70 months). The mean ablation volume was 6888 mm 3 . Median hippocampal ablation was 65%, with a median amygdala ablation of 43%. At last follow-up, 11 (48%) of these patients were seizure free. There was no correlation between ablation volume and seizure freedom (p = 0.69). There was also no correlation between percent ablation of the amygdala (p = 0.28) or hippocampus (p = 0.82) and seizure outcomes. Twelve patients underwent formal testing with computational visual fields. Visual field changes were seen in 67% of patients who underwent testing. Comparing the 5 patients with clinically noticeable visual field deficits to the rest of the cohort showed no significant difference in ablation volume between those patients with visual field deficits and those without (p = 0.94). There were 11 patients with follow-up neuropsychological testing. Within this group, verbal learning retention was 76% in the patients with left-sided procedures and 89% in those with right-sided procedures. CONCLUSIONS In this study, there was no significant correlation between the ablation volume after LiTT and seizure outcomes. Visual field deficits were common in formally tested patients, much as in patients treated with open temporal lobectomy. Further studies are required to determine the role of amygdalohippocampal ablation.
Risk of de novo aneurysm formation in patients with a prior diagnosis of ruptured or unruptured aneurysm: systematic review and meta-analysis
Giordan, Enrico , Rangel-Castilla, Leonardo , Murad, M. Hassan , Brinjikji, Waleed , Murad, M Hassan , Lanzino, Giuseppe , Rangel-Castilla, Leonardo

Mayo Clinic

Journal of Neurosurgery | July 6, 2018 | Volume: No volume available | Issue: No issue available | Pages: 1-11

10.3171/2018.1.jns172450 | PMID 29979115 Get It

OBJECTIVE De novo aneurysms are rare entities periodically discovered during follow-up imaging. Little is known regarding the frequency with which these lesions form or the time course. This systematic review and meta-analysis was undertaken to estimate the incidence of de novo aneurysms and to determine risk factors for aneurysm formation. METHODS The authors searched multiple databases for studies of patients with unruptured and ruptured aneurysms describing the rate of de novo aneurysm formation. The primary outcome was incidence of de novo aneurysm formation. A meta-analysis was performed using a random-effects model. The authors examined the associations of multiple aneurysms, prior subarachnoid hemorrhage, smoking, sex, age at presentation, and hypertension with de novo aneurysm formation. RESULTS The meta-analysis included 14,968 aneurysm patients who received imaging follow-up from 35 studies. The overall incidence of de novo aneurysm formation was 2% (95% CI 2%–3%) over a mean follow-up time of 8.3 years. The estimated incidence density was 0.3%/patient-year. There was no statistically significant difference in rates of de novo aneurysm formation between patients who had ruptured aneurysms and those with unruptured aneurysms. In 8 studies, 11.2% of de novo aneurysms were found in patients with ≤ 5 years of follow-up and 88.8% were found at > 5 years. The mean time to rupture for de novo aneurysms was 10 years. CONCLUSIONS This systematic review demonstrates that formation of de novo aneurysms is rare. Overall, routine screening for de novo aneurysms is likely to be of low yield and could be performed at time intervals of at least 5 to 10 years.
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial
Solomon, Scott D. , Rizkala, Adel R. , Lefkowitz, Martin, Shi, Victor , Gong, Jianjian , Anavekar, Nagesh S., Arango, Juan Luis, Arenas, J., Ben-Gal, T., Boytsov, S. А. , Chen, Chen-Huan, Cleland, John G.F. , DUENGEN, H, Echeverría, Luis Eduardo , Filippatos, Gerasimos , Flammer, Andreas J. , Galinier, Michel , Godoy, Armando, Gonçalvesová, Eva , Janssens, Stefan , Katova, Tzvetana, Køber, Lars , Lelonek, Małgorzata , Linssen, Gerard C.M. , Lund, Lars H. , O’Meara, Eileen , Perrone, Sergio V. , Ranjith, Naresh , Saito, Yoshihiko , Saraiva, Jose F. Kerr, Shah, Sanjiv J. , Seferović, Petar , Sibulo, Antonio S., Sim, David , Sweitzer, Nancy K. , Taurio, Jyrki , Vinereanu, Dragoş , Vrtovec, Bojan , Yılmaz, Mehmet Birhan , Zhou, Jingmin , Zweiker, Robert , Anand, Inder S. , Maggioni, Aldo P. , Pieske, Burkert , Redfield, Margaret M. , Rouleau, Jean L. , Veldhuisen, Dirk J. van , Zannad, Faı̈ez , Zile, Michael R. , McMurray, John J.V. , Felker, G. Michael , Zile, Michael R , Anand, Inder S , Maggioni, Aldo P , McMurray, John J V , Shah, Sanjiv J , Solomon, Scott David , Anker, Stefan D. , Atar, Dan , Chopra, Vijay , Comín‐Colet, Josep , Merkely, Béla , Miličić, Davor , Oh, Byung‐Hee , Senni, Michele , Sim, David , Jr., Jiri Widimsky , Ge, Junbo , Lam, Carolyn S.P. , Martínez‐Pastor, Felipe , Packer, Milton , Pfeffer, Marc Alan , Køber, Lars , Cleland, John G F

Mayo Clinic

Circulation: Heart Failure | July 6, 2018 | Volume: 11 | Issue: 7 | Pages: No page available

10.1161/circheartfailure.118.004962 | PMID 29980595 Get It

Background: To describe the baseline characteristics of patients with heart failure and preserved left ventricular ejection fraction enrolled in the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in HFpEF) comparing sacubitril/valsartan to valsartan in reducing morbidity and mortality. Methods and Results: We report key demographic, clinical, and laboratory findings, and baseline therapies, of 4822 patients randomized in PARAGON-HF, grouped by factors that influence criteria for study inclusion. We further compared baseline characteristics of patients enrolled in PARAGON-HF with those patients enrolled in other recent trials of heart failure with preserved ejection fraction (HFpEF). Among patients enrolled from various regions (16% Asia-Pacific, 37% Central Europe, 7% Latin America, 12% North America, 28% Western Europe), the mean age of patients enrolled in PARAGON-HF was 72.7±8.4 years, 52% of patients were female, and mean left ventricular ejection fraction was 57.5%, similar to other trials of HFpEF. Most patients were in New York Heart Association class II, and 38% had ≥1 hospitalizations for heart failure within the previous 9 months. Diabetes mellitus (43%) and chronic kidney disease (47%) were more prevalent than in previous trials of HFpEF. Many patients were prescribed angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (85%), β-blockers (80%), calcium channel blockers (36%), and mineralocorticoid receptor antagonists (24%). As specified in the protocol, virtually all patients were on diuretics, had elevated plasma concentrations of N-terminal pro-B-type natriuretic peptide (median, 911 pg/mL; interquartile range, 464–1610), and structural heart disease. Conclusions: PARAGON-HF represents a contemporary group of patients with HFpEF with similar age and sex distribution compared with prior HFpEF trials but higher prevalence of comorbidities. These findings provide insights into the impact of inclusion criteria on, and regional variation in, HFpEF patient characteristics. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01920711.
Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma
Ailawadhi, Sikander , Dholaria, Bhagirathbhai , Khurana, Sharad , Sher, Taimur , Alegria, Victoria R., Paulus, Aneel , Ailawadhi, Meghna, Mehta, Aditya , Chanan‐Khan, Asher , Alegria, Victoria, Dholaria, Bhagirathbhai R , Ailawadhi, Sikander , Paulus, Aneel , Roy, Vivek

Mayo Clinic

British Journal of Haematology | July 6, 2018 | Volume: 185 | Issue: 2 | Pages: 347-350

10.1111/bjh.15458 | PMID 29978498 Get It